Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (1458)	1/28/1998 2:07:00 PM
From: Webhead	Read Replies (1) \| Respond to of 1762

Genentech's quarterly report (from 1/22) shows terriffic initial sales of rituxan, particularly since they occurred over a holiday season where sales are traditionally soft ( or so I am told!). If these rates are an accurate reflection of demand then Idec shouldn't have any trouble meeting the $140 Million sales figure for this year. Ed --------- "In 1997, Genentech launched a new BioOncology initiative that includes the marketed product Rituxan as well as the oncology products that Genentech has under clinical development. Genentech and IDEC launched Rituxan on December 16, 1997, and recorded initial sales of $5.5 million for 1997. While Genentech is encouraged by these sales figures, not enough time has passed for these figures to be indicative of future sales, and the figures may reflect pent up demand for the product. "